Symphony Thrombectomy System is designed to efficiently maximize clot removal with a focus on minimizing blood loss. CAMPBELL ...

On October 22, 2024, we acquired privately-held Opus Genetics Inc., a clinical-stage gene therapy company focused on IRDs, in ...

Despite regulation changes in the Chinese healthcare industry, we think CSPC is well-positioned to maintain relatively strong revenue growth. First, generic drugs normally face the most severe price ...

How can you design your own SWAN portfolio? The broader stock market ... that are designed to offer the economic benefit/loss of the covered calls written on the Nasdaq index.

That would normally be a blow to any portfolio. But those losses were more than offset by ... Montreal-based WSP is an international engineering and design firm. This stock went into a brief ...

We recently published a list of Carl Icahn Stock Portfolio ... As an illustration of the troubles the activist investor faces, Icahn Capital LP saw losses exceeding $3 billion from Q4 2023 ...

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and ...

I'll take a minute and highlight here that adjusting on a pro forma basis, the $39.6 million net loss for the $54 million of total non-cash unrealized and realized loan portfolio losses taken in ...

In 2020, the Office of Naval Intelligence told Congress that Chinese naval ships are now “in many cases comparable” to their U.S. counterparts and that China was “quickly closing the gap” in design ...

Pulse Biosciences, Inc. (NASDAQ: PLSE) Q4 2024 Earnings Call Transcript March 27, 2025 Pulse Biosciences, Inc. beats earnings ...

India’s equity benchmarks ended nearly flat on Tuesday, pausing after a six-session rally that erased their 2025 losses, as ...

Operator: Greetings. Welcome to the Quantum Computing Inc. Fourth Quarter 2024 Shareholder Update Conference Call. At this ...